D. Benjamin

发表

Design, synthesis and selection of DNA-encoded small-molecule libraries.

Baoguang Zhao, Cecil E. Rise, M. Gefter, 2009, Nature chemical biology.

Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction

D. Benjamin, J. Hunter, Fu Li, 2019, Molecular Cancer Therapeutics.

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.

P. Carter, F. Hernandez-Ilizaliturri, H. Gerber, 2009, Blood.

Erratum: Design, synthesis and selection of DNA-encoded small-molecule libraries

Baoguang Zhao, Cecil E. Rise, M. Gefter, 2009 .

Contribution of linker stability to the activities of anticancer immunoconjugates.

Damon L. Meyer, D. Benjamin, P. Senter, 2008, Bioconjugate chemistry.

The Fucosylation Inhibitor, 2-Fluorofucose, Inhibits Vaso-Occlusion, Leukocyte-Endothelium Interactions and NF-ĸB Activation in Transgenic Sickle Mice

G. Vercellotti, D. Benjamin, P. Senter, 2015, PloS one.

Development of orally active inhibitors of protein and cellular fucosylation

P. Burke, D. Benjamin, P. Senter, 2013, Proceedings of the National Academy of Sciences.

Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.

Kim K. Emmerton, D. Benjamin, N. Okeley, 2016, Cancer research.

Cancer Therapy : Preclinical Clinical Cancer Research Intracellular Activation of SGN-35 , a Potent Anti-CD 30 Antibody-Drug Conjugate

D. Benjamin, P. Senter, S. Alley, 2010 .

The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity

D. Benjamin, P. Senter, S. Alley, 2009, Journal of Pharmacology and Experimental Therapeutics.

Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates.

D. Benjamin, S. Hengel, S. Alley, 2016, Bioanalysis.

Orally active fumagillin analogues: transformations of a reactive warhead in the gastric environment.

C. D. Thompson, Amy A Sarjeant, C. Arico-Muendel, 2013, ACS medicinal chemistry letters.

Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates

D. Benjamin, M. Jonas, C. Law, 2017, Molecular Cancer Therapeutics.

Abstract 3694: Relationship betweenin vivoantitumor activity of ADC and payload release in preclinical models

Kim K. Emmerton, D. Benjamin, N. Okeley, 2014 .

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

John F. Valliere-Douglass, T. Lewis, Sa A. Wang, 2017, Molecular Cancer Therapeutics.

Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.

D. Benjamin, K. Gordon, H. V. Van Epps, 2017, Blood.

Metabolites of PPI-2458, a Selective, Irreversible Inhibitor of Methionine Aminopeptidase-2: Structure Determination and In Vivo Activity

C. D. Thompson, C. Arico-Muendel, D. Benjamin, 2013, Drug Metabolism and Disposition.

DMD048355 814..826

C. D. Thompson, C. Arico-Muendel, D. Benjamin, 2013 .

The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer

D. Stover, A. Raitano, Z. An, 2016, Molecular Cancer Therapeutics.

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

D. Benjamin, P. Senter, S. Alley, 2010, Clinical Cancer Research.

SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML

John F. Valliere-Douglass, R. Walter, D. Benjamin, 2015 .

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

I. Bernstein, P. Burke, R. Walter, 2013, Blood.

SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

A. Nesterova, D. Benjamin, Leia M. Smith, 2014, Molecular Cancer Therapeutics.

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

D. Benjamin, E. Feldman, S. Alley, 2015 .

Abstract 3833: SEA-BCMA: A highly active enhanced antibody for multiple myeloma

D. Benjamin, Luke S Manlove, Martha E. Anderson, 2018, Immunology.

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

I. Bernstein, P. Burke, R. Walter, 2012 .

Large Molecule Therapeutics SGN – LIV 1 A : A Novel Antibody – Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

A. Nesterova, D. Benjamin, Leia M. Smith, 2014 .

1 SGN-LIV 1 A : A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

A. Nesterova, D. Benjamin, Leia M. Smith, 2014 .

Carbamate analogues of fumagillin as potent, targeted inhibitors of methionine aminopeptidase-2.

C. D. Thompson, G. Hannig, C. Arico-Muendel, 2009, Journal of medicinal chemistry.

Abstract 4634: Engineered cysteine drug conjugates show potency and improved safety

D. Benjamin, D. Sussman, Martha E. Anderson, 2012 .

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

P. Carter, D. Benjamin, S. Alley, 2018, Protein engineering, design & selection : PEDS.